oYo-Link® mIgG1 DM4 Antibody L

oYo-Link® DM4 Antibody-Drug Conjugation 

In vitro, research use only. Not recommended for in vivo experiments.

oYo-Link® DM4 is an Antibody-Drug Conjugation reagent allowing for rapid, site-specific labeling of DM4 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DM4 drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding.

Furthermore, site-specific labeling limits 1-2 DM4 drugs to be attached per antibody, providing precise antibody-drug conjugate ratios.

As a synthetic derivative of the microtubule-targeted agent ravtansine, also known as the maytansinoid DM4, the DM4 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with ravtansine and enhances tumor-specific delivery.

Generate antibody-DM4 conjugates in only 30-sec hands on time, 2 hours total.

The antibody labeling procedure simply requires mixing oYo-Link® DM4 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm).

Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins.

Application: Antibody conjugation reagent for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays.

oYo-Link® DM4 Cell Killing Assay for SKBR3 cells

 

The figure above shows results of a cytotoxic cell assay illustrating the highly specific cell-killing nature of oYo-Link®’s antibody-drug conjugate. Her2-positive SKBR3 cells were incubated with oYo-Link® DM4 labeled anti-CD20 (Rituximab), oYo-Link® DM4 labeled anti-Her2 (Trastuzumab), and oYo-Link® DM4 in isolation.  The real advantages come from oYo-Link’s versatility and compatibility with nearly any buffer or concentration. The unconjugated oYo-Link® DM4 does not result in cell death, as shown above. The compounds were added 24 hours after cell seeding and the data was evaluated at 96 hours after cell seeding. Assay was performed and analyzed by the xCELLigence™ RTCA SP instrument.

 

oYo-Link® DM4 Antibody Crosslinking Data

 

oYo-Link DM4 Photo-crosslinking Efficiency shown by SDS-PAGE: using a 4-12% Tris Gel shows an upwards shift of the antibody heavy chain following site-specific photo-crosslinking with oYo-Link. *Note the size and migration for each unreacted oYo-Link product will differ.